MedPath

Nicotinamide riboside

Generic Name
Nicotinamide riboside
Drug Type
Small Molecule
Chemical Formula
C11H15N2O5
CAS Number
1341-23-7
Unique Ingredient Identifier
0I8H2M0L7N
Background

Nicotinamide riboside is under investigation in clinical trial NCT03432871 (Nicotinamide Riboside and Mitochondrial Biogenesis).

Clinical Trials
Related News

Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis

Phase 2
Not yet recruiting
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Other: Placebos for zinc and nicotinamide riboside
First Posted Date
2024-08-23
Last Posted Date
2024-08-23
Lead Sponsor
Cedars-Sinai Medical Center
Target Recruit Count
60
Registration Number
NCT06567717
Locations
🇺🇸

Cedars-Sinai, Los Angeles, California, United States

NAD Supplementation and Vascular Health in PAD

Phase 1
Active, not recruiting
Conditions
Peripheral Artery Disease
Interventions
First Posted Date
2024-08-02
Last Posted Date
2024-08-15
Lead Sponsor
University of Oklahoma
Target Recruit Count
8
Registration Number
NCT06534944
Locations
🇺🇸

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside

Not Applicable
Not yet recruiting
Conditions
Ataxia Telangiectasia
Interventions
First Posted Date
2024-03-22
Last Posted Date
2024-04-18
Lead Sponsor
The University of Queensland
Target Recruit Count
10
Registration Number
NCT06324877
Locations
🇦🇺

Queensland Children's Hospital, Brisbane, Queensland, Australia

The Effect of NAD Supplementation on Brain Vascular Health in Aging

Phase 4
Recruiting
Conditions
Aging
Interventions
Drug: Placebo
First Posted Date
2022-08-02
Last Posted Date
2024-05-13
Lead Sponsor
University of Oklahoma
Target Recruit Count
214
Registration Number
NCT05483465
Locations
🇺🇸

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection

Phase 2
Completed
Conditions
SARS-CoV-2 Infection
Acute Kidney Injury
Interventions
Drug: Placebo
First Posted Date
2021-03-26
Last Posted Date
2023-12-26
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
28
Registration Number
NCT04818216
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

🇺🇸

University Health Systems, San Antonio, Texas, United States

🇺🇸

The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

and more 1 locations

Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19 Illness (Long-COVID)

Phase 4
Completed
Conditions
Covid19
Sequelae of; Infection
Cognitive Symptom
Interventions
First Posted Date
2021-03-22
Last Posted Date
2024-03-20
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
70
Registration Number
NCT04809974
Locations
🇺🇸

Clinical Translational Research Unit, Boston, Massachusetts, United States

Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure

Early Phase 1
Active, not recruiting
Conditions
Heart Failure, Systolic
Metabolic Disturbance
Heart Failure NYHA Class IV
Interventions
Other: Placebo
First Posted Date
2020-08-27
Last Posted Date
2025-03-25
Lead Sponsor
University of Washington
Target Recruit Count
32
Registration Number
NCT04528004
Locations
🇺🇸

University of Washington, Seattle, Washington, United States

Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia

Early Phase 1
Recruiting
Conditions
Mild Alzheimer Disease
Mild Cognitive Impairment
Interventions
First Posted Date
2020-06-12
Last Posted Date
2024-11-20
Lead Sponsor
Mclean Hospital
Target Recruit Count
50
Registration Number
NCT04430517
Locations
🇺🇸

McLean Hospital, Belmont, Massachusetts, United States

NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy

Phase 2
Active, not recruiting
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
Drug: Placebo capsules
First Posted Date
2019-10-02
Last Posted Date
2024-07-09
Lead Sponsor
Donna Hammond, PhD
Target Recruit Count
48
Registration Number
NCT04112641
Locations
🇺🇸

Donna Hammond, Iowa City, Iowa, United States

Nicotinamide Riboside in Hospitalized Patients

Phase 1
Completed
Conditions
Inflammation
Acute Illness
Interventions
Drug: Placebo
First Posted Date
2019-10-01
Last Posted Date
2024-05-20
Lead Sponsor
Oslo University Hospital
Target Recruit Count
57
Registration Number
NCT04110028
Locations
🇳🇴

Oslo University Hospital, Oslo, Norway

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy